

Adrian J C Bloor

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9359915/publications.pdf>

Version: 2024-02-01

20
papers

1,996
citations

933447

10
h-index

940533

16
g-index

20
all docs

20
docs citations

20
times ranked

2700
citing authors

#	ARTICLE	IF	CITATIONS
1	Long-term results and GvHD after prophylactic and preemptive donor lymphocyte infusion after allogeneic stem cell transplantation for acute leukemia. <i>Bone Marrow Transplantation</i> , 2022, 57, 215-223.	2.4	36
2	A national service for delivering <sc>CD19 CAR</sc> in large B-cell lymphoma â€” The <sc>UK</sc> real-world experience. <i>British Journal of Haematology</i> , 2022, 198, 492-502.	2.5	40
3	Comparison of fludarabineâ€”melphalan and fludarabineâ€”treosulfan as conditioning prior to allogeneic hematopoietic cell transplantationâ€”a registry study on behalf of the EBMT Acute Leukemia Working Party. <i>Bone Marrow Transplantation</i> , 2022, 57, 1269-1276.	2.4	6
4	SARSâ€”CoVâ€”2 screening for asymptomatic health care workers in UK stem cell transplant units. <i>British Journal of Haematology</i> , 2021, 192, e37-e38.	2.5	1
5	Second allogeneic transplants for multiple myeloma: a report from the EBMT Chronic Malignancies Working Party. <i>Bone Marrow Transplantation</i> , 2021, 56, 2367-2381.	2.4	1
6	Durable Responses and Low Toxicity After Fast Off-Rate CD19 Chimeric Antigen Receptor-T Therapy in Adults With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia. <i>Journal of Clinical Oncology</i> , 2021, 39, 3352-3363.	1.6	59
7	Influence of pretransplant inflammatory bowel disease on the outcome of allogeneic hematopoietic stem cell transplantation: a matched-pair analysis study from the Transplant Complications Working Party (TCWP) of the EBMT. <i>Bone Marrow Transplantation</i> , 2021, 56, 3084-3087.	2.4	2
8	Letemovir prophylaxis in T-cellâ€”depleted transplants: breakthrough and rebound infections in the postmarketing setting. <i>Blood Advances</i> , 2021, 5, 4500-4503.	5.2	6
9	Poor outcome of patients with COVID-19 after CAR T-cell therapy for B-cell malignancies: results of a multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party and the European Hematology Association (EHA) Lymphoma Group. <i>Leukemia</i> , 2021, 35, 3585-3588.	7.2	72
10	Use of Cryopreserved Allogeneic PBSC Results in Delayed Engraftment and Increased Incidence of Poor Graft Function. <i>Blood</i> , 2021, 138, 1778-1778.	1.4	0
11	Second Malignant Neoplasms (SMN) in Myeloma Patients Post Stem Cell Transplant (SCT). <i>Blood</i> , 2021, 138, 1839-1839.	1.4	0
12	Comparative Study of Unrelated and Haploidentical Donor Hematopoietic Cell Transplant for Chronic Myeloid Leukemia with Post Transplant Cyclophosphamide As Graft-Versus-Host Disease Prophylaxis: A Study from the Chronic Malignancies Working Party of EBMT. <i>Blood</i> , 2021, 138, 3954-3954.	1.4	0
13	Production, safety and efficacy of iPSC-derived mesenchymal stromal cells in acute steroid-resistant graft versus host disease: a phase I, multicenter, open-label, dose-escalation study. <i>Nature Medicine</i> , 2020, 26, 1720-1725.	30.7	187
14	Prophylactic donor lymphocyte infusion after allogeneic stem cell transplantation in acute leukaemia â€” a matched pair analysis by the Acute Leukaemia Working Party of EBMT. <i>British Journal of Haematology</i> , 2019, 184, 782-787.	2.5	82
15	Real-World Data of High-Grade Lymphoma Patients Treated with CD19 CAR-T in England. <i>Blood</i> , 2019, 134, 767-767.	1.4	27
16	Assessment of ibrutinib plus rituximab in front-line CLL (FLAIR trial): study protocol for a phase III randomised controlled trial. <i>Trials</i> , 2017, 18, 387.	1.6	31
17	Recent advances in therapy of chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2016, 174, 351-367.	2.5	18
18	Chemotherapy plus Ofatumumab at Standard or Mega dose in relapsed CLL (COSMIC) trial: study protocol for a phase II randomised controlled trial. <i>Trials</i> , 2016, 17, 456.	1.6	1

#	ARTICLE	IF	CITATIONS
19	Survival outcomes and treatment costs for patients with doubleâ€refractory chronic lymphocytic leukaemia (<scp>DR</scp>â€<scp>CLL</scp>). British Journal of Haematology, 2015, 169, 449-452.	2.5	0
20	Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia. New England Journal of Medicine, 2014, 371, 213-223.	27.0	1,427